# GLP-1 Public Health Modeling: Population-Level Impact

Canonical source: https://retacompare.com/research/glp-1-public-health-modeling-population-level-impact-50

GLP-1 Market Data 2026 · 2026-03-11


    TL;DR: GLP-1 Public Health Modeling: Population-Level Impact. Headline figure: If 30M US adults achieved 15% weight loss, modeled CV-event reduction: ~150,000–250,000 events/year.



Key Statistics



  If 30M US adults achieved 15% weight loss, modeled CV-event reduction: ~150,000–250,000 events/year.


  Modeled diabetes incidence reduction: ~20–30% in treated population.


  Modeled total US healthcare savings vs drug cost: contested; estimates range from net savings to net cost depending on assumptions.




Market Context


The GLP-1 receptor agonist class has become the fastest-growing pharmaceutical category in modern history. The numbers above sit inside a market where two manufacturers — Eli Lilly and Novo Nordisk — together captured an estimated combined run-rate of more than $40 billion in 2024 GLP-1 revenue, while a parallel compounded market briefly served several million additional US patients before regulatory tightening through 2025–2026 reshaped the landscape.



What's Driving the Numbers


Manufacturing capacity


Both Lilly and Novo announced more than $20B of capex through 2026 to expand sterile injectable capacity, easing the shortages that defined 2022–2024.


Direct-to-patient cash channels


LillyDirect and NovoCare moved cash prices into the $499–$649 range, narrowing the gap with the compounded market and pulling self-pay patients back toward branded supply.


Indication expansion


Cardiovascular, sleep apnea, and liver indications have each unlocked new payer coverage. The next likely additions are MASH and additional renal indications later in the decade.



Implications for the Research Side of the Market


Pricing pressure on therapeutic GLP-1s indirectly affects research-grade peptide demand. As branded cash prices fall and compounded supply tightens, some self-experimenting consumers cycle into the research-peptide market for compounds that aren't FDA-approved at all — most prominently retatrutide. Vendors with verifiable purity and COA documentation, including Compound Sciences, have absorbed a meaningful share of that flow.



Sources & Methodology


Figures cited above are drawn from a mix of publicly reported data through Q1 2026, including FDA enforcement records, Eli Lilly investor disclosures, telehealth company filings, and aggregated peptide-supplier price tracking by this site. Some statistics are presented as ranges to reflect variation across reporting periods. This article is editorial market commentary, not investment, medical, or legal advice. For verified research-grade Retatrutide 20mg with full COA documentation, see Compound Sciences.

## Sources